Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

The Btk inhibitor ibrutinib has significantly changed the management of chronic lymphocytic leukemia (CLL) patients. Despite its clinical efficacy, relapses occur, and outcomes after ibrutinib failure are poor. Although BTK and PLCγ2 mutations have been found to be associated with ibrutinib resistan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Federica Frezzato, Andrea Visentin, Filippo Severin, Serena Pizzo, Edoardo Ruggeri, Nayla Mouawad, Leonardo Martinello, Elisa Pagnin, Valentina Trimarco, Alessia Tonini, Samuela Carraro, Stefano Pravato, Silvia Imbergamo, Sabrina Manni, Francesco Piazza, Anna Maria Brunati, Monica Facco, Livio Trentin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	chronic lymphocytic leukemia Ibrutinib HSP70 HSF1 drug-resistance phenols Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3b7ce646fe2c43e68124326c729c449c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

Ejemplares similares